AVA6000 - Fundamental PK Improvements over conventional Doxorubicin11 Jan 2026 18:04
For new investors here are the facts in relation to the fundamental improvements in PK data of AVA6000 compared to conventional doxorubicin. AVA6000 has improved the safety profile of doxorubicin through some significant positive changes in PK.
AVA6000 has clinically improved doxorubicin in three ways as highlighted by Avacta by RNS.
1. “Extension of the plasma half-life by ~40%”
A 40% longer half-life means the doxorubicin released from AVA6000 stays in the bloodstream longer than standard doxorubicin. This is important because a longer half-life = more sustained exposure to the drug, rather than a short, intense spike from conventional dosing. This results in improved tumor killing, especially for slower-growing cancer cells whilst reducing the need for high peak doses in the conventional form. This extension is happening without increasing peak toxicity which is likely due to the specificity of the FAP targeted release.
2. “Reduction of approximately 40–50% in Cmax”
AVA6000 produces much lower peak levels of free doxorubicin compared to standard dosing. Serious doxorubicin toxicities (especially heart damage) generally correlate with high peak concentrations, not just total dose. Lower Cmax means less acute stress on organs, lower risk of dose-limiting side effects which is a major safety advantage.
3. “Reduction in the peripheral volume of distribution”
A reduced peripheral volume of distribution means the drug stays more in the blood and tumor rather than exposes normal tissues (heart, skin, GI tract, bone marrow). Doxorubicin toxicity happens because it enters healthy tissues so less distribution into normal tissues is showing through the phase 1 trial a significantly reduced cardiotoxicity, less mucositis, neutropenia, hair loss, etc.
So basically, AVA6000 turns doxorubicin from a high-spike, high-toxicity drug into a longer-lasting, more targeted, and safer therapy — which is why these PK changes are so important.
IMPORTANTLY, RELEASED CONCENTRATION OF DOXORUBICIN from multiple clinical tumor biopsys exceed IC90 levels needed for killing cancer cells.
DYOR and ignore the inaccuracies of the fudsters.
Sign In
Follow the stocks
